��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Long term efficacy and safety of Dimethyl Fumarate: A 3 year follow-up in a single MS center

Topic Multiple Sclerosis

Presentation(s) P6 - (-)

Poster/Presentation
Number 335

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Peiqing Qian, MD PRESENTER	Dr. Qian has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. Dr. Qian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Qian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Qian has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for BMS.
Julia H. Joo (Swedish Medical Center)	No disclosure on file
	No disclosure on file
James D. Bowen, MD (Swedish Neuroscience Institute)	Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen IDEC. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for BristolMyers Squibb. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Bowen has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Bowen has received research support from Biogen IDEC. The institution of Dr. Bowen has received research support from Genentech. The institution of Dr. Bowen has received research support from Genzyme. The institution of Dr. Bowen has received research support from Novartis. The institution of Dr. Bowen has received research support from Roche.